Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Principles of Management

Primary and metastatic brain tumors are a heterogeneous group of neoplasms with varied outcomes and management strategies. Primary brain tumors range from pilocytic astrocytomas, which are very uncommon, noninvasive, and surgically curable, to glioblastoma multiforme, the most common intraparenchymal brain tumor in adults, which is highly invasive and virtually incurable. Likewise, patients with metastatic brain disease may have rapidly progressive systemic disease or no systemic cancer at all. These patients may have one or dozens of brain metastases, and they may have a malignancy that is highly responsive or, alternatively, highly resistant to radiation or chemotherapy. Because of this marked heterogeneity, the prognostic features and treatment options for brain tumors must be carefully reviewed on an individual basis and sensitively communicated to each patient. In addition, CNS tumors are associated with a range of symptoms and complications, such as edema, seizures, endocrinopathy, fatigue, psychiatric disorders, and venous thromboembolism, that can seriously impact quality of life. The involvement of an interdisciplinary team, including neurosurgeons, radiation therapists, oncologists, neurologists, and neuroradiologists, is a key factor in the appropriate management of these patients. For any subtype of malignant brain lesions, the NCCN CNS Panel encourages a thorough multidisciplinary review of each patient case once the pathology results are available.

Treatment Principles

Several important principles guide surgical and radiation therapy (RT) for adults with brain tumors. Regardless of tumor histology, neurosurgeons generally perform debulking surgery for primary brain tumors, except multiforme, the most common intraparenchymal brain tumor in adults, which is highly invasive and virtually incurable. Likewise, patients with metastatic brain disease may have rapidly progressive systemic disease or no systemic cancer at all. These patients may have one or dozens of brain metastases, and they may have a malignancy that is highly responsive or, alternatively, highly resistant to radiation or chemotherapy. Because of this marked heterogeneity, the prognostic features and treatment options for brain tumors must be carefully reviewed on an individual basis and sensitively communicated to each patient. In addition, CNS tumors are associated with a range of symptoms and complications, such as edema, seizures, endocrinopathy, fatigue, psychiatric disorders, and venous thromboembolism, that can seriously impact quality of life. The involvement of an interdisciplinary team, including neurosurgeons, radiation therapists, oncologists, neurologists, and neuroradiologists, is a key factor in the appropriate management of these patients. For any subtype of malignant brain lesions, the NCCN CNS Panel encourages a thorough multidisciplinary review of each patient case once the pathology results are available.
Oligodendrogliomas, particularly those that have chromosomal loss of combined 1p19q, have been reported to be sensitive to alkylator chemotherapy. If gross total resection (GTR) is achieved, consider further observation. Regular follow-up is essential for patients receiving observation alone after resection.

Postoperative MRI should be performed within 72 hours after surgery.

Consider testing for deletions in 1p19q if tumor has components of oligodendroglioma for prognostic purposes.

At recurrence, there is a high propensity for these tumors to undergo malignant transformation. Sixty percent or more of astrocytomas and 40%-50% of oligodendrogliomas will eventually undergo transformation to a higher grade. (Chaichana KL, McGirt MJ, Laterra J, et al. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 2010;112:10-17.)

High-risk features: 3 or more of: Astrocytoma, Age >40 y, KPS <70, tumor dimension >6 cm, tumor crossing midline, preoperative neurological deficit of more than minor degree. One or no deletions on 1p and 19q, IDH1 or IDH2 not mutated, increased perfusion on imaging are also adverse factors that may be considered.

Low-risk features: Oligodendroglioma or mixed oligoastrocytoma, <40 y, KPS >70, tumor dimension <6 cm, minor or no neurologic deficit, 1p and 19q codeleted, IDH1 or IDH2 mutated.

See Principles of Brain Tumor Imaging (BRAIN-A).

Consider a multidisciplinary review in treatment planning, especially once pathology is available (See Principles of Brain Tumor Management [BRAIN-E], available online, in these guidelines, at NCCN.org).

Surgery is generally recommended, but serial observations are appropriate for selected patients.

Consider testing for deletions in 1p19q if tumor has components of oligodendroglioma for prognostic purposes.

Low-risk features: Oligodendroglioma or mixed oligoastrocytoma, <40 y, KPS >70, tumor dimension <6 cm, minor or no neurologic deficit, 1p and 19q codeleted, IDH1 or IDH2 mutated.

High-risk features: 3 or more of: Astrocytoma, Age >40 y, KPS <70, tumor dimension >6 cm, tumor crossing midline, preoperative neurological deficit of more than minor degree. One or no deletions on 1p and 19q, IDH1 or IDH2 not mutated, increased perfusion on imaging are also adverse factors that may be considered.

Regular follow-up is essential for patients receiving observation alone after resection.

If gross total resection (GTR) is achieved, consider further observation.

See Principles of Brain Tumor Radiation Therapy (BRAIN-C).

Oligodendrogliomas, particularly those that have chromosomal loss of combined 1p19q, have been reported to be sensitive to alkylator chemotherapy. Consider chemotherapy for these patients.

See Principles of Brain Tumor and Spinal Cord Systemic Therapy (BRAIN-D).
Oligodendrogliomas, particularly those that have chromosomal loss of combined 1p19q, have been reported to be sensitive to alkylator chemotherapy.

If gross total resection (GTR) is achieved, consider further observation.

Regular follow-up is essential for patients receiving observation alone after resection.

Postoperative MRI should be performed within 72 hours after surgery.

Surgery is generally recommended, but serial observations are appropriate for selected patients.

Consider testing for deletions in 1p19q if tumor has components of oligodendroglioma for prognostic purposes.

Consider a multidisciplinary review in treatment planning, especially once pathology is available (See Principles of Brain Tumor Management [BRAIN-E].)

See Principles of Brain Tumor Radiation Therapy (BRAIN-C).

See Principles of Brain Tumor and Spinal Cord Systemic Therapy (BRAIN-D).

At recurrence, there is a high propensity for these tumors to undergo malignant transformation. Sixty percent or more of astrocytomas and 40%-50% of oligodendrogliomas will eventually undergo transformation to a higher grade. (Chaichana KL, McGirt MJ, Laterra J, et al. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 2010;112:10-17.)
Clinical trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.
### Central Nervous System Cancers, Version 2.2013  
**ANAPLASTIC GLIOMAS/GLIOBLASTOMA**

<table>
<thead>
<tr>
<th>PATHOLOGY</th>
<th>ADJUVANT TREATMENT</th>
<th>FOLLOW-UP&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
</table>
| Anaplastic oligodendroglioma Anaplastic oligoastrocytoma 1p19q codeleted   | Fractionated external-beam RT<sup>1</sup> and PCV chemotherapy (category 1)<sup>k,l</sup>  
|                                                                            | or                                                                                 |                       |
|                                                                            | Fractionated external-beam RT<sup>1</sup> and temozolomide chemotherapy<sup>k,m</sup>  
|                                                                            | or                                                                                 |                       |
|                                                                            | PCV or temozolomide chemotherapy<sup>k</sup> (category 2B)                          |                       |
| Anaplastic oligodendroglioma Anaplastic oligoastrocytoma 1p19q uni- or non-deleted  
Anaplastic astrocytoma                                                       | Fractionated external-beam RT<sup>1</sup>(category 1)                             |                       |
|                                                                            | or                                                                                 |                       |
|                                                                            | Fractionated external-beam RT<sup>1</sup> and temozolomide chemotherapy<sup>k</sup>  
|                                                                            | or                                                                                 |                       |
|                                                                            | PCV or temozolomide chemotherapy<sup>k</sup>                                      |                       |
| Anaplastic gliomas Poor performance status (KPS <70)                        | Fractionated external-beam RT<sup>1</sup> (hypofractionated [preferred] or standard)  
|                                                                            | or                                                                                 |                       |
|                                                                            | PCV or temozolomide chemotherapy (category 2B)<sup>k</sup>                         |                       |
|                                                                            | or                                                                                 |                       |
|                                                                            | Palliative/best supportive care                                                    |                       |
| Good performance status (KPS ≥70)                                          | Fractionated external-beam RT<sup>1</sup> + concurrent and adjuvant temozolomide,  
|                                                                            | for age ≤70 y (category 1)<sup>k,o,p,q</sup>                                    |                       |
|                                                                            | or                                                                                 |                       |
|                                                                            | Fractionated external-beam RT<sup>1</sup> + concurrent and adjuvant temozolomide  
|                                                                            | for age >70 y<sup>k,o,p</sup>                                                     |                       |
|                                                                            | or                                                                                 |                       |
|                                                                            | Fractionated external-beam RT<sup>1</sup> (hypofractionated) (category 1)          |                       |
|                                                                            | for age >70 y<sup>l</sup>                                                          |                       |
|                                                                            | or                                                                                 |                       |
|                                                                            | Chemotherapy<sup>k</sup> (temozolomide if methylguanine methyl-transferase [MGMT] promotor methylation positive) for age >70 y |                       |
| Poor performance status (KPS <70)                                          | Fractionated external-beam RT<sup>1</sup> (hypofractionated or standard)            |                       |
|                                                                            | or                                                                                 |                       |
|                                                                            | Chemotherapy<sup>k</sup>                                                          |                       |
|                                                                            | or                                                                                 |                       |
|                                                                            | Palliative/best supportive care                                                    |                       |
|                                                                            | MRI 2-6 wk after RT, then every 2-4 mo for 2-3 y, then less frequently             |                       |
|                                                                            | See Recurrence (GLIO-4)                                                           |                       |

<sup>a</sup>This pathway includes the classification of mixed anaplastic oligoastrocytoma (AOA), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and other rare anaplastic gliomas.

<sup>b</sup>See Principles of Brain Tumor Radiation Therapy (BRAIN-C).

<sup>c</sup>See Principles of Brain Tumor Imaging (BRAIN-A).

<sup>d</sup>See Principles of Brain Tumor and Spinal Cord Systemic Therapy (BRAIN-D).


<sup>g</sup>Combination of agents may lead to increased toxicity or radiographic changes.


<sup>i</sup>Duration of treatment for glioblastomas beyond 6 months is unknown. Duration of therapy for anaplastic astrocytoma is unknown.


GLIO-2  
GLIO-3
**Clinical trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

---

**ANAPLASTIC GLIOMAS/GLIOBLASTOMA**

**Central Nervous System Cancers, Version 2.2013**

---

### RECURRENCE

- **Diffuse or multiple**
  - **Recurrent disease**
    - Anaplastic oligodendroglioma
    - Anaplastic oligoastrocytoma
    - Anaplastic astrocytoma
    - Anaplastic glialomas
    - Glioblastoma

### TREATMENT

- **Resectable**
  - **Resection + carmustine (BCNU) wafer**
  - **Palliative/best supportive care if poor performance status**
  - **Systemic chemotherapy**
  - **Surgery for symptomatic, large lesion**
  - **Consider alternating electric field therapy (for glioblastoma) (category 2B)**

- **Unresectable**
  - **Resection without carmustine (BCNU) wafer**
  - **Palliative/best supportive care if poor performance status**
  - **Systemic chemotherapy**
  - **Consider reirradiation (category 2B)**
  - **Consider alternating electric field therapy (for glioblastoma) (category 2B)**

---

**GLIO-4**

---

This pathway includes the classification of mixed anaplastic oligoastrocytoma (AOA), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and other rare anaplastic gliomas.

See Principles of Brain Tumor Radiation Therapy (BRAIN-C).

See Principles of Brain Tumor and Spinal Cord Systemic Therapy (BRAIN-D).

Treatment with carmustine wafer, reirradiation, or multiple prior systemic therapies, may impact enrollment in some adjuvant clinical trials.

Consider MR spectroscopy, MR perfusion, or brain PET to rule out radiation necrosis.

Within the first 3 months after completion of RT and concomitant temozolomide, diagnosis of recurrence can be indistinguishable from pseudoprogression on neuroimaging. With pseudoprogression, stabilization or improvement should be expected within 3 mo of the end of radiotherapy.

Anaplastic oligodendrogliomas have been reported to be especially sensitive to chemotherapy. Chemotherapy using temozolomide or nitrosourea-based regimens may be appropriate.


Especially if long interval since prior RT and/or if there was a good response to prior RT.

---

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 11 Number 9 | September 2013

---

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 11 Number 9 | September 2013
**RADIOLOGIC PRESENTATION**
Contrast-enhanced MRI compatible with primary brain tumor

**CLINICAL IMPRESSION**
Maximal safe resection possible
Maximal safe resection not possible

**SURGERY**
Stereotactic biopsy or Open biopsy or Partial resection

See Postoperative Staging (AMED-2)

---

*Adult Medulloblastoma and Supratentorial PNET

---

**Excluding esthesioneuroblastoma.**

**See Principles of Brain Tumor Imaging (BRAIN-A).**

**Consider a multidisciplinary review in treatment planning, before surgery and once pathology is available (See Principles of Brain Tumor Management [BRAIN-E], available online, in these guidelines, at NCCN.org).**

**Placement of ventriculoperitoneal (VP) shunt for management of hydrocephalus is acceptable if needed.**

**See Principles of Brain Tumor Surgery (BRAIN-B).**

**Strongly recommend referring patient to a brain tumor center to be evaluated for possible further, more complete surgical resection.**

AMED-1
**Central Nervous System Cancers, Version 2.2013**

### MEDULLOBLASTOMA

**Postoperative Staging**

- **Standard risk for recurrence:**
  - No evidence of metastasis (brain, spine, CSF, extraneural)
  - Small volume residual disease (contrast volume <1.5 cm²)
  - Classic or desmoplastic histology

- **High risk for recurrence:**
  - Unresectable tumor or residual tumor >1.5 cm²
  - Disseminated disease within or outside of the neuroaxis
  - Large cell/anaplastic medulloblastoma
  - Supratentorial PNET

**Adjuvant Treatment**

- **Craniospinal radiation**
  - or
  - Concurrent chemoRT followed by post-radiation chemotherapy

*Adult Medulloblastoma and Supratentorial PNET*

---

**Notes:**

- Excluding esthesioneuroblastoma.
- Within 24-72 hours.
- Spine MRI should be delayed by at least 2-3 weeks after surgery to avoid postsurgical artifacts.
- Lumbar puncture should be performed after spine MRI. Lumbar puncture for CSF should be delayed at least 2 weeks after surgery to avoid possible false-positive cytology.
- Bone scan, CT scans of chest, abdomen and pelvis, and bone marrow biopsy only if clinically indicated.
- If only biopsy is possible, consider preirradiation chemotherapy followed by an attempt at resection.
- See Principles of Brain Tumor Radiation Therapy (BRAIN-C).
- See Principles of Brain Tumor and Spinal Cord Systemic Therapy (BRAIN-D).
- Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24:4202-4208. Omission of vincristine during radiotherapy phase of therapy or dose modification may be required for adults because they do not tolerate this regimen as well. Data supporting vincristine’s use have been found in pediatric trials only. Patients should be closely monitored for neurologic toxicity with periodic examinations.
- Recommend a platinum-based chemotherapy regimen such as either of the treatment arms used in the Children’s Oncology Group study referenced in footnote "o".

**AMED-2**

**Clinical trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.
**MEDULLOBLASTOMA**

<table>
<thead>
<tr>
<th>FOLLOW-UP&lt;sup&gt;b&lt;/sup&gt;</th>
<th>RECURRENCE</th>
<th>CLINICAL STAGING</th>
<th>SURGERY</th>
<th>TREATMENT FOR PROGRESSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain MRI:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>every 3 mos for 2 y;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>then every 6 months for 3 y; then yearly</td>
<td>Localized brain recurrence</td>
<td>Maximal safe resection</td>
<td>Chemotherapy &lt;sup&gt;n&lt;/sup&gt; and/or Additional radiation, such as stereotactic radiosurgery, &lt;sup&gt;s&lt;/sup&gt; after resection or High-dose chemotherapy &lt;sup&gt;n&lt;/sup&gt; with autologous stem cell reinfusion&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>For patients with previous spine disease, concurrent spine imaging as clinically indicated</td>
<td>Recurrent disease</td>
<td>MRI of brain and spine</td>
<td>Disseminated disease&lt;sup&gt;r&lt;/sup&gt;</td>
<td>Chemotherapy &lt;sup&gt;n&lt;/sup&gt; or Palliative/best supportive care, including focal radiation, if indicated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>*Adult Medulloblastoma and Supratentorial PNET</sup>

<sup>a</sup>Excluding esthesioneuroblastoma.

<sup>b</sup>See Principles of Brain Tumor Imaging (BRAIN-A).

<sup>c</sup>See Principles of Brain Tumor and Spinal Cord Systemic Therapy (BRAIN-D).

<sup>d</sup>If clinically indicated. If patient was treated with radiation only at diagnosis, then a bone scan should be part of restaging imaging at time of recurrence, even if patient is asymptomatic.

<sup>e</sup>Consider resection for palliation of symptoms where indicated.


<sup>1</sup>Only if the patient is without evidence of disease after surgery or conventional-dose reinduction chemotherapy.

---

**Central Nervous System Cancers, Version 2.2013**

**ADJUVANT TREATMENT**

- Concurrent chemoRT followed by post-radiation chemotherapy
- Craniospinal radiation and post-radiation chemotherapy
- Chemotherapy
- Additional radiation, such as stereotactic radiosurgery, after resection
- High-dose chemotherapy with autologous stem cell reinfusion

**STAGING**

- Postoperative

**CLINICAL STAGING**

<table>
<thead>
<tr>
<th>STAGING</th>
<th>POST OPERATIVE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Excluding esthesioneuroblastoma.</td>
</tr>
</tbody>
</table>

**Recommended Chemotherapy Regimen**

- Platinum-based chemotherapy regimen such as either of the treatment arms used in the Children's Oncology Group study referenced in AMED-2

**Note:**


**Consider:**

- Palliative/best supportive care, including focal radiation, if indicated

---

**Version 2.2013, 04-25-13 ©2013 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.**

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 11 Number 9 | September 2013
**Central Nervous System Cancers, Version 2.2013**

**Clinical trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

**LIMITED (1–3) METASTATIC LESIONS**

---

### WORKUP

**1-3 metastatic lesions on MRI**

- **Known history of cancer**
  - If concern exists regarding diagnosis of CNS lesions
  - Stereotactic or open biopsy/resection or Subtotal resection

- **No known history of cancer**
  - Suspected tumor found outside CNS
  - Biopsy or resection of tumor outside CNS

  - Chest x-ray/CT
  - Abdominal/pelvic CT
  - Consider body FDG-PET if 2-3 lesions and no primary found
  - Other tests as indicated

  - No other readily accessible tumor for biopsy
  - Stereotactic or open biopsy/resection

---

**CLINICAL PRESENTATION**

- **Known history of cancer**
- **No known history of cancer**

---

| LTD-1 |

---

- **See Principles of Brain Tumor Imaging (BRAIN-A).**
- **Consider a multidisciplinary review in treatment planning, especially once pathology is available (See Principles of Brain Tumor Management [BRAIN-E], available online, in these guidelines, at NCCN.org).**
<table>
<thead>
<tr>
<th>CLINICAL PRESENTATION</th>
<th>PRIMARY TREATMENT</th>
<th>FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disseminated systemic disease with poor systemic treatment options</td>
<td>WBRT(^9) Consider chemotherapy(^h) (category 2B)</td>
<td>MRI every 3 mo for 1 y then as clinically indicated</td>
</tr>
<tr>
<td>Newly diagnosed or stable systemic disease or Reasonable systemic treatment options</td>
<td>Surgical resection, followed by WBRT(^1) (category 1) or stereotactic radiosurgery (SRS) or SRS(^3) + WBRT (category 1 for 1 metastasis) or SRS(^1) alone (category 2A)</td>
<td>MRI every 3 mo for 1 y then as clinically indicated</td>
</tr>
<tr>
<td>Unresectable</td>
<td>WBRT(^9) and/or SRS</td>
<td>MRI every 3 mo for 1 y then as clinically indicated</td>
</tr>
</tbody>
</table>

- See Principles of Brain Tumor Imaging (BRAIN-A).
- Consider surgery to relieve mass effect.
- Solid brain metastases with systemic non-primary CNS lymphoma are not well defined, but treatment may include systemic treatment, whole-brain radiotherapy, or focal RT.
- The decision to resect a tumor may depend on the need to establish histologic diagnosis, the size of the lesion, its location, and institutional expertise. For example, smaller (<2 cm), deep, asymptomatic lesions may be considered for treatment with SRS versus larger (>2 cm), symptomatic lesions that may be more appropriate for surgery. (Ewend MG, Morris DE, Carey LA, et al. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J Natl Compr Cancer Netw 2008; 6:505-513.)
- See Principles of Brain Tumor Surgery (BRAIN-B).
- See Principles of Brain Tumor Radiation Therapy (BRAIN-C).
- Chemotherapy may be considered in select patients (eg, patients who have asymptomatic brain metastases that are otherwise small and who have not had prior chemotherapy). Treatment as per the regimens of the primary tumor.
Central Nervous System Cancers, Version 2.2013

Clinical trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

LIMITED (1–3) METASTATIC LESIONS

RECURRENT

TREATMENT

RECURRENT

TREATMENT

Recurrent disease; local site

Surgery or Single-dose or fractionated stereotactic RT or WBRT or Consider chemotherapy

Systemic disease progression, with limited systemic treatment options and poor PS

No prior WBRT

WBRT or Palliative/Best supportive care

Recurrent disease; distant brain ± local recurrence

Surgery or Single-dose or fractionated stereotactic RT or WBRT or Consider chemotherapy

Palliative/Best supportive care or Reirradiation, if prior positive response to RT

1-3 lesions

WBRT or Consider chemotherapy

Prior WBRT

Surgery or Single-dose or fractionated stereotactic RT or WBRT or Consider chemotherapy

WBRT or Palliative/Best supportive care

Previous surgery

Previous WBRT or Prior SRS

Surgery or Single-dose or fractionated stereotactic RT or WBRT or Consider chemotherapy

If patient relapses

WBRT or Palliative/Best supportive care

>3 lesions

WBRT or Consider chemotherapy

See Principles of Brain Tumor Imaging (BRAIN-A).

See Principles of Brain Tumor and Spinal Cord Systemic Therapy (BRAIN-D).

Local or systemic chemotherapy.

If patient had previous SRS with a good response >6 mo, then reconsider SRS if imaging supports active tumor and not necrosis.

See Principles of Brain Tumor Radiation Therapy (BRAIN-C).

After stereotactic radiosurgery, recurrence on radiograph can be confounded by treatment effects, consider tumor tissue sampling if there is a high index of suspicion of recurrence.

See Principles of Brain Tumor Management [BRAIN-E], available online, in these guidelines, at NCCN.org.

As part of diagnostic evaluation, neuroimaging modalities such as MRI, DW-MRI, MRI-SPECT, or PET scan may be considered.

See Principles of Brain Tumor Radiation Therapy (BRAIN-C).

Consider surgery to relieve mass effect.


LTD-3/LTD-4
## Central Nervous System Cancers, Version 2.2013

### MULTIPLE (>3) METASTATIC LESIONS

<table>
<thead>
<tr>
<th>CLINICAL PRESENTATION&lt;sup&gt;a&lt;/sup&gt;</th>
<th>WORKUP</th>
<th>PRIMARY TREATMENT&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Known history of cancer</strong></td>
<td>If concern exists regarding diagnosis of CNS lesions&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Stereotactic or open biopsy/resection&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Multiple (&gt;3) metastatic lesions on CT or MRI&lt;sup&gt;b&lt;/sup&gt;</strong></td>
<td></td>
<td>WBRT or SRS&lt;sup&gt;e,f&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>No known history of cancer</strong></td>
<td>Chest x-ray/CT</td>
<td>No other readily accessible tumor for biopsy</td>
</tr>
<tr>
<td></td>
<td>Abdominal/pelvic CT</td>
<td>Stereotactic or open biopsy/resection&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Consider body FDG-PET if no primary found</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other tests as indicated</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>See Principles of Brain Tumor Imaging (BRAIN-A).

<sup>b</sup>Consider a multidisciplinary review in treatment planning, especially once pathology is available (See Principles of Brain Tumor Management [BRAIN-E], available online, in these guidelines, at NCCN.org).

<sup>c</sup>As part of diagnostic evaluation, neuroimaging modalities such as MRI, DW-MRI, MRI-SPECT, or PET scan may be considered.

<sup>d</sup>Consider surgery to relieve mass effect.

<sup>e</sup>See Principles of Brain Tumor Radiation Therapy (BRAIN-C).


---

**Version 2.2013, 04-25-13 ©2013 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.**

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 11 Number 9 | September 2013
Central Nervous System Cancers, Version 2.2013

Clinical trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.
FOLLOW-UP: then as clinically indicated every 3 mo for 1 y, MRI.

See Principles of Brain Tumor and Spinal Cord Systemic Therapy (BRAIN-D).
See Principles of Brain Tumor Radiation Therapy (BRAIN-C).
See Principles of Brain Tumor Imaging (BRAIN-A).

MU-2 disease

Recurrent treatment options
disease or
Stable systemic treatment options with limited systemic progression,
Systemic disease

TREATMENT
Reirradiation or
supportive care
Palliative/best Chemotherapy or Reirradiation or Surgery

This is a list of imaging modalities available and used in neuro-oncology primarily to make treatment decisions. The most common use for MR spectroscopy, MR perfusion, and body PET is to differentiate radiation necrosis from active tumor, as this might obviate the need for surgery or the discontinuation of an effective therapy.

PRINCIPLES OF BRAIN TUMOR IMAGING

- MRI of the brain and spine (+ contrast):
  - Gold standard
  - Provides a "static" picture of tumors
  - Benefits: provides a reasonably good delineation of tumors; higher-grade tumors and brain leptomeningeal metastasis usually enhance; lower-grade tumors usually do not enhance.
  - Limitations: Sensitive to movement; metallic objects cause artifact; patients with implantable devices cannot have an MRI; claustrophobia may be an issue

- CT of the brain and spine (+ contrast):
  - Should be used in patients who cannot have an MRI
  - Benefits: claustrophobia or implantable devices are not an issue; can be done faster than an MRI
  - Limitations: lacks resolution of MRI, especially in posterior fossa

- MR Spectroscopy: assess metabolites within tumors and normal tissue
  - May be useful in differentiating tumor from radiation necrosis; may be helpful in grading tumors or assessing response
  - Area most abnormal would be the best place to target for a biopsy
  - Limitations: tumors near vessels, air spaces, or bone; extra time in MRI; other limitations as noted under MRI above

- MR perfusion: measures cerebral blood volume in tumors
  - May be useful in differentiating grade of tumor or tumor versus radiation necrosis; area of highest perfusion would be the best place to biopsy
  - Limitations: tumors near vessels, air spaces, or bone; small-volume lesions; tumors in the spinal cord; extra time in MRI; other limitations as noted under MRI above

- Brain FDG-PET scanning: assess metabolism within tumor and normal tissue by using radiolabeled tracers
  - May be useful in differentiating tumor from radiation necrosis but has some limitations; may also correlate with tumor grade or provide the optimal area for biopsy
  - Limitations: accuracy of interpretations; availability of equipment and isotopes

This is a list of imaging modalities available and used in neuro-oncology primarily to make treatment decisions. The most common use for MR spectroscopy, MR perfusion, and body PET is to differentiate radiation necrosis from active tumor, as this might obviate the need for surgery or the discontinuation of an effective therapy.

These guidelines are intended to assist practitioners in making decisions about treatment for members of their practice, based on the best available evidence. These guidelines should be used in conjunction with clinical expertise and consideration of each patient's individual circumstances, including age, performance status, and other factors.

1 The imaging modalities listed may not be available at every institution.

PRINCIPLES OF BRAIN TUMOR SURGERY

GUIDING PRINCIPLES

- Maximal tumor removal when appropriate
- Minimal surgical morbidity
- Accurate diagnosis

FACTORS

- Age
- Performance status (PS)
- Feasibility of decreasing the mass effect with surgery
- Resectability, including number of lesions, location of lesions, time since last surgery (recurrent patients)
- New versus recurrent tumor
- Suspected pathology: benign vs. malignant, possibility of other noncancer diagnoses, projected natural history

OPTIONS

- Gross total resection where feasible
- Stereotactic biopsy
- Open biopsy/debulking followed by planned observation or adjuvant therapy
- Chemotherapy implants, when indicated (See footnote “g” on GLIO-1)

TISSUE

- Sufficient tissue to pathologist for neuropathology evaluation and molecular correlates.
- Frozen section analysis when possible to help with intraoperative decision making
- Review by experienced neuropathologist

- Postoperative MRI should be performed within 24-72 hours for gliomas and parenchymal brain tumors to determine the extent of resection.
- The extent of resection should be judged on the postoperative study and used as a baseline to assess further therapeutic efficacy or tumor progression.
**PRINCIPLES OF BRAIN TUMOR RADIATION THERAPY**

### Low-Grade Gliomas (Grades I/II)
- Tumor volumes are best defined using pre- and postoperative imaging, usually FLAIR and or T2 signal abnormality on MRI for gross tumor volume (GTV). Clinical target volume (CTV; GTV plus 1- to 2-cm margin) should receive 45-54 Gy in 1.8- to 2.0-Gy fractions.
- SRS has not been established to have a role in the management of low-grade gliomas. Phase I trials using SRS do not support its role as initial treatment.

### High-Grade Gliomas (Grades III/IV)
- The GTV is best defined using pre- and postoperative MRI using enhanced T1 and FLAIR/T2. The GTV is expanded by 2-3 cm (CTV) to account for subdiagnostic tumor infiltration. Fields are usually reduced for the last phase of the treatment (boost).
- The recommended dose is 60 Gy in 1.8- to 2.0-Gy fractions. A slightly lower dose, 55-57 Gy, can be applied when the tumor volume is very large (gliomatosis) or for grade III astrocytoma.
- In poorly performing patients or the elderly, a hypofractionated accelerated course was found to be effective with the goal of completing the treatment in 3-4 weeks. Total doses vary between 40 and 50 Gy.

### Adult Medulloblastoma and Supratentorial PNET:
- **Standard risk for recurrence:**
  - Conventional dose: 30-36 Gy CSI and boosting the primary brain site to 55.8 Gy without adjuvant chemotherapy
  - Reduced dose: 23.4 Gy CSI and boosting the primary brain site to 55.8 Gy with adjuvant chemotherapy
  - High risk for recurrence: 36 Gy with boosting primary brain site to 55.8 Gy

### Brain Metastases
- Whole-brain radiotherapy: doses vary between 20 and 40 Gy delivered in 5-20 fractions. The standard regimens include 30 Gy in 10 fractions or 37.5 Gy in 15 fractions. Nevertheless, 20 Gy in 5 fractions is a good option in poor performers.
- Stereotactic radiosurgery: recommend maximum marginal doses of 24, 18, or 15 Gy according to tumor volume is recommended (RTOG 90-05).[^2]

[^1]: Regimen supported by data from pediatric trials only.

[^2]: FLAIR: Fluid-attenuated inversion recovery

---


---

**Clinical trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.
### Adult Medulloblastoma and Supratentorial PNET

**Adjuvant treatment**
- Weekly vincristine during craniospinal radiation therapy followed by either of the following regimens:
  - Cisplatin, cyclophosphamide, and vincristine
  - Cisplatin, lomustine, and vincristine
- Recurrence/salvage therapy
  - No prior chemotherapy
  - High-dose cyclophosphamide ± etoposide
  - Carboplatin, etoposide, and cyclophosphamide
  - Cisplatin, etoposide, and cyclophosphamide
  - High-dose chemotherapy with autologous stem cell reinfusion in patients who achieve a complete response with conventional doses of salvage chemotherapy or have no residual disease after re-resection
- Prior chemotherapy
  - High-dose cyclophosphamide ± etoposide
  - Oral etoposide
  - Temozolomide
  - High-dose chemotherapy with autologous stem cell reinfusion in patients who achieve a complete response with conventional doses of salvage chemotherapy or have no residual disease after re-resection

### Limited (1-3) Metastatic or Multiple (>3) Metastatic Lesions

- **Recurrence disease**
  - Treatment as per the regimens of the primary tumor
  - Carmustine wafer
  - Temozolomide 5/28 schedule
- **Organ-specific therapy**
  - High-dose methotrexate (breast and lymphoma)
  - Cape vorzinib ± lapatinib, cisplatin, etoposide (breast)
  - Topotecan (small cell lung)

---

### PRINCIPLES OF BRAIN TUMOR AND SPINAL CORD SYSTEMIC THERAPY

#### Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma (excluding pilocytic astrocytoma)

- **Adjuvant treatment**
  - Temozolomide
  - Recurrence or progressive, low-grade disease:
    - Temozolomide
    - Nitrosourea
    - Combination PCV (lomustine + procarbazine + vincristine)
    - Platinum-based regimens

#### Anaplastic Gliomas

- **Adjuvant treatment**
  - Temozolomide or PCV with deferred RT
  - Concurrent (with RT) temozolomide, 75 mg/m² daily
- **Recurrence/salvage therapy**
  - Temozolomide
  - Nitrosourea
  - Combination PCV
  - Bevacizumab
  - Bevacizumab + chemotherapy
  - Irinotecan, carmustine/lomustine, temozolomide
  - Cyclophosphamide (category 2B)
  - Platinum-based regimens
  - Etoposide

#### Anaplastic Oligodendroglioma

- **Adjuvant treatment**
  - RT and PCV for 1p/19q co-deleted (category 1)

#### Glioblastoma

- **Adjuvant treatment**
  - Concurrent (with RT) temozolomide, 75 mg/m² daily
  - Post RT temozolomide, 150-200 mg/m² 5/28 schedule
  - Temozolomide, 150-200 mg/m² 5/28 schedule
- **Recurrence/salvage therapy**
  - Bevacizumab
  - Bevacizumab + chemotherapy
  - Irinotecan, carmustine/lomustine, temozolomide
  - Temozolomide
  - Nitrosourea
  - Combination PCV
  - Cyclophosphamide (category 2B)
  - Platinum-based regimens

---

1 For patients not previously treated.
2 Discontinuation of bevacizumab after progression may be associated with rapid neurologic deterioration and bevacizumab may be continued in these circumstances.
3 Platinum-based regimens include cisplatin or carbo platinum.
4 Omission of vincristine during radiotherapy phase of therapy or dose modification may be required for adults, because they do not tolerate this regimen as well. Data supporting vincristine’s use have been found in pediatric trials only. Patients should be closely monitored for neurologic toxicity with periodic exams.
5 Use agents active against primary tumor.
Central Nervous System Cancers, Version 2.2013

PRINCIPLES OF BRAIN TUMOR AND SPINAL CORD SYSTEMIC THERAPY (REFERENCES)


Central Nervous System Cancers, Version 2.2013

PRINCIPLES OF BRAIN TUMOR AND SPINAL CORD SYSTEMIC THERAPY (REFERENCES)

41 Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases—the UK experience. Br J Cancer 2010;102:995-1002.
provide the best outcome for their patients if they remove as much tumor as possible (maximal safe resection), minimize surgical morbidity, and ensure an accurate diagnosis through providing sufficient representative tumor tissue. Decisions regarding aggressiveness of surgery for primary brain lesions are complex and depend on the 1) age and performance status (PS) of the patient; 2) proximity to “eloquent” areas of the brain; 3) feasibility of decreasing the mass effect with aggressive surgery; 4) resectability of the tumor (including the number and location of lesions); and 5) time since last surgery in patients with recurrent disease.\textsuperscript{4} Surgical options include stereotactic biopsy, open biopsy, subtotal resection, or complete resection (gross total resection). The pathologic diagnosis is critical and may be difficult to determine accurately without sufficient tumor tissue. Review by an experienced neuropathologist is highly recommended. In addition, a postoperative MRI scan, with and without contrast, should be obtained 24 to 72 hours after surgery to document the extent of disease after surgical intervention.

Radiation oncologists use several different treatment modalities in patients with primary brain tumors, including brachytherapy, stereotactic fractionated RT, and stereotactic radiosurgery (SRS). Standard fractionated external-beam RT (EBRT) is the most common approach, whereas hypofractionation is emerging as an option for select patients (eg, elderly and patients with compromised performance). RT for patients with primary brain tumors is administered within a limited field (tumor and surround), whereas whole-brain RT (WBRT) and SRS are used primarily for brain metastases.

Clinicians are advised to consult the algorithm sections, “Principles of Brain Tumor Imaging” (BRAIN-A, page 1129) and “Principles of Brain Tumor Surgery” (BRAIN-B, page 1129), for further discussion of these diagnostic and treatment modalities. The dose of radiation administered varies depending on the pathology results, as seen in “Principles of Brain Tumor Radiation Therapy” (BRAIN-C, page 1130). Appropriate chemotherapeutic and biologic regimens for each tumor subtype are listed under “Principles of Brain Tumor and Spinal Cord Systemic Therapy” (BRAIN-D, page 1131).

**Low-Grade Infiltrative Astrocytomas and Oligodendrogliomas**

Diffusely infiltrative low-grade gliomas (eg, astrocytomas, oligodendrogliomas, mixed oligoastrocytomas) are a diverse group of relatively uncommon malignancies classified as grade II under the WHO grading system.\textsuperscript{5} Multivariate analysis of 2 phase III trials conducted by the EORTC revealed that age of 40 years or older, astrocytoma histology, largest dimension of tumor as 6 cm or greater, tumor crossing midline, and presence of neurologic deficit before resection were unfavorable prognostic factors.\textsuperscript{6} In a separate validation study of 203 patients treated in a North American Intergroup trial, high-risk patients as defined by EORTC criteria (>2 risk factors) had a median overall survival of 3.9 years compared with 10.8 years in the low-risk group.\textsuperscript{7}

Seizure is a common symptom (81%) of low-grade gliomas, and is more frequently associated with oligodendrogliomas.\textsuperscript{8} The median duration from onset of symptoms to diagnosis ranges from 6 to 17 months. These tumors typically are nonenhancing, low-attenuation/low-signal-intensity lesions on CT or MRI scans.

Diffuse astrocytomas are poorly circumscribed and invasive, and most gradually evolve into higher-grade astrocytomas. Although these were traditionally considered benign, they can behave aggressively and will undergo anaplastic transformation within 5 years in approximately half of patients.\textsuperscript{9,10} The most common noninfiltrative astrocytomas are pilocytic astrocytomas, which are circumscribed, often surgically resectable, and rarely transform; however, the NCCN algorithm does not encompass pilocytic astrocytomas because these tumors are curable with surgery alone.

Oligodendrogliomas are thought to arise from oligodendrocytes, whereas mixed oligoastrocytomas probably develop from a common glial stem cell. Radiographically, low-grade oligodendrogliomas appear well demarcated, occasionally contain calcifications, and do not enhance with contrast. The typical “fried egg” appearance of these tumors is evident in paraffin but not in frozen sections. More than half of oligodendrogliomas have specific molecular genetic alterations (allelic losses of chromosomes 1p and 19q) that can help distinguish them from other types of gliomas.\textsuperscript{11} Grade II oligodendrogliomas have a much better 5-year survival rate (70%) than mixed gliomas (56%) and astrocytomas (37%).\textsuperscript{12}
Treatment Overview

Surgery: The best management strategy for infiltrative low-grade gliomas has yet to be defined.\textsuperscript{13} Surgery remains an important diagnostic and therapeutic modality. The primary surgical goal is to provide adequate tissue for a pathologic diagnosis and grading. Needle biopsies are often performed when lesions are in deep or critical regions of the brain. Biopsy results can be misleading, because gliomas often have varying degrees of cellularity, mitoses, or necrosis from one region to another; thus, small samples can provide a lower histologic grade.

The role of maximal tumor resection in low-grade astrocytomas remains unresolved. Because these tumors are relatively uncommon, published series generally include patients treated for decades, which introduces additional variables. For example, the completeness of surgical excision was based on the surgeon’s report in older studies. This approach is relatively unreliable when compared with assessment using modern postoperative imaging studies. Furthermore, most patients also received RT, and thus the net effect of the surgical procedure on outcome is difficult to evaluate. Most of the available retrospective biomedical literature suggests a survival benefit from aggressive surgical resection,\textsuperscript{14-17} although some data reported no difference.\textsuperscript{18} Maximal safe resection may also delay or prevent malignant progression\textsuperscript{19-21} and recurrence.\textsuperscript{22}

Biological considerations also favor an attempt at a complete excision of an astrocytoma. First, the tumor may contain higher-grade foci, which may not be reflected in a small specimen. Second, complete excision may decrease the risk of future dedifferentiation to a more malignant astrocytoma.\textsuperscript{19} Third, a large tumor burden is removed, which also may enhance the effect of RT. As a result of these considerations, the general recommendation for treating an astrocytoma is to first attempt as complete an excision of tumor as possible (based on postsurgical MRI verification) without compromising function. Low-grade oligodendrogliomas are often amenable to total excision because of their location in the frontal lobes and distinct tumor margins. However, for tumors that involve eloquent areas, total removal may not be feasible and an aggressive approach could result in neurologic deficits.

Radiation Therapy: No consensus exists regarding the proper timing of postoperative EBRT for low-grade gliomas. Some oncologists advocate immediate fractionated EBRT, whereas others delay radiation until tumor progression is evident. In the EORTC 22845 randomized trial of early versus delayed RT in adult patients,\textsuperscript{23} those with low-grade gliomas were randomly assigned to either 54-Gy postoperative radiation or no immediate therapy. In an interim analysis, the 5-year disease-free survival was better with immediate postoperative radiation (44% vs 37%; \( P = .02 \)). However, overall survival was similar, indicating that deferring postoperative therapy can be an option for a select group of patients. Long-term follow-up of these patients showed that overall survival was not increased in patients who had received early RT (7.4 vs 7.2 years); however, seizures were better controlled.\textsuperscript{24} Although delaying radiation in young, healthy patients without progressive neurologic decline can be controversial, there is a consensus to proceed with immediate postoperative radiation in older patients after a less-than-total resection, because their survival is as poor as patients with anaplastic astrocytoma. When radiation is deferred, regular follow-up is essential for patients receiving observation alone after resection. However, a consensus exists that high-risk patients with low-grade gliomas as defined by the EORTC experience benefit from early, upfront RT in terms of progression-free and overall survivals.

When radiation is given to patients with low-grade gliomas, it is administered with restricted margins. A T2-weighted and/or fluid-attenuated inversion recovery (FLAIR) MRI scan is the best means for evaluating tumor extent, because these tumors enhance weakly or not at all. The clinical target volume is defined by the FLAIR or T2-weighted tumor with a 1- to 2-cm margin. Every attempt should be made to decrease the radiation dose outside the target volume. This can be achieved with 3-dimensional planning or intensity-modulated RT. The standard radiation dose for low-grade astrocytomas is 45 to 54 Gy, delivered in 1.8- to 2.0-Gy fractions. The selection of 45 to 54 Gy as the standard dose range is based on its relative safety when applied to a limited volume of the brain and on the lack of evidence for increased efficacy with higher doses.\textsuperscript{25,26} In a randomized trial conducted by the EORTC in patients with low-grade astrocytomas, no survival difference was observed when 45.0 Gy was compared with 59.4 Gy.\textsuperscript{27} With a median follow-up of 6 years, the 5-year disease-free survival and overall survival were the
same. A combined NCCTG (North Central Cancer Treatment Group), RTOG, and ECOG study randomized patients to receive either 50.4 Gy in 28 fractions or 64.8 Gy in 36 fractions. With a median follow-up of 6.3 years, the 5-year disease-free and overall survival rates were again the same, indicating that lower doses of RT are probably as effective as higher doses of radiation for low-grade gliomas. Enthusiasm for SRS in low-grade gliomas has waned because of insufficient evidence for therapeutic advantage.

**Systemic Therapy:** Chemotherapy is not a traditional mainstay of upfront treatment for low-grade gliomas. Some data support temozolomide as adjuvant therapy, and it is included as a category 2B recommendation based on nonuniform panel consensus. A phase II trial of temozolomide achieved a 61% objective response rate in 46 patients. Alternate protracted dosing schedules have produced response rates of 20% to 52%. RTOG conducted a clinical trial (RTOG 9802) that allowed observation alone for favorable patients (age <40 with gross total resection) and randomly assigned unfavorable patients (age ≥40 following any resection or younger patients who were subtotally resected) to postoperative radiation with or without combination PCV (lomustine [CCNU], procarbazine, and vincristine). Results have been presented in abstract form. In the favorable arm, the 5-year progression-free survival and overall survival rates were 50% and 94%, respectively. In the unfavorable arm, the addition of chemotherapy to radiation conferred a survival advantage beyond 2 years.

In the absence of randomized trial data, several regimens are currently considered acceptable for recurrence or progressive disease, including temozolomide, nitrosourea, PCV, and platinum-based therapy.

Patients with low-grade oligodendrogliomas, especially those with 1p/19q deletions, may represent favorable candidates for chemotherapy in light of good response rates reported in literature; however, this has never been prospectively determined.

**NCCN Recommendations**

**Primary and Adjuvant Treatment:** When possible, maximal safe resection is recommended for low-grade infiltrative astrocytomas and oligodendrogliomas, and the actual extent of resection should be documented with a T2-weighted or FLAIR MRI scan within 72 hours after surgery. If the tumor is found to have components of oligodendroglioma, 1p/19q deletion testing should be considered because it is a favorable prognostic factor. Managing the disease through serial observation alone is appropriate for selected patients. The NCCN CNS Panel also discussed the role of the isocitrate dehydrogenase 1 or 2 (IDH1, IDH2) genes in low-grade gliomas. Mutations in the IDH genes are common and are reported to be a significant marker of positive prognosis. However, routine IDH testing as a recommendation is not included in the algorithm at this point because its impact on treatment is still unclear.

The following are considered low-risk features for low-grade gliomas: age of 40 years or younger; Karnofsky performance status (KPS) of 70 or greater; minor or no neurologic deficit; oligodendroglioma or mixed oligoastrocytoma; tumor dimension less than 6 cm; 1p and 19q codeletion; and IDH1 or IDH2 mutation. Patients are categorized as being high risk if they have 3 or more of the following: age older than 40 years, KPS less than 70, tumor larger than 6 cm, tumor crossing midline, or preoperative neurologic deficit of more than minor degree. Other adverse factors to consider include increased perfusion on imaging; one or no deletion on 1p and 19q; and wild-type IDH1 or IDH2. If gross total resection is achieved, most low-risk patients may be observed without adjuvant therapy. However, close follow-up is essential because more than half of these patients eventually experience disease progression. Low-grade gliomas can behave aggressively in high-risk patients, and adjuvant radiation or chemotherapy (category 2B for chemotherapy) is recommended for this group, although select patients may be observed.

Patients who only had a stereotactic biopsy, open biopsy, or subtotal excision should be treated with immediate fractionated EBRT or chemotherapy (category 2B), particularly if their symptoms are uncontrolled or progressive. Because of concerns about the neurotoxicity of RT, patients with asymptomatic residual tumors or stable symptoms may also be followed until their disease progresses. Patients should be followed using MRI every 3 to 6 months for 5 years, and then at least annually.

**Recurrence:** At the time of recurrence, surgery is recommended (if resectable) followed by chemotherapy in patients who previously underwent fractionated EBRT. At progression after chemotherapy, the options...
are to 1) consider another regimen; 2) consider reirradiation; and 3) provide palliative/best supportive care. Reirradiation is a good choice if the patient has been progression-free for more than 2 years after prior RT, the new lesion is outside the target of previous RT, or the recurrence is small and geometrically favorable. If the patient has not previously received radiation, they should first undergo surgery if the lesion is resectable. Patients may receive RT or chemotherapy after surgery (category 2B for chemotherapy).

Anaplastic Gliomas and Glioblastomas

Anaplastic astrocytomas (grade III) and glioblastomas (grade IV astrocytomas) are the most common of the primary malignant brain tumors in adults, accounting for 7% and 54% of all gliomas, respectively. Glioblastoma is the most lethal brain tumor, with only a third of patients surviving for 1 year and fewer than 5% living beyond 5 years. The 5-year survival rate for anaplastic astrocytoma is 27%. The most important prognostic factors identified in an analysis of 1578 patients are histologic diagnosis, age, and PS.

High-grade astrocytomas diffusely infiltrate surrounding tissues and frequently cross the midline to involve the contralateral brain. Patients with these neoplasms often present with symptoms of increased intracranial pressure, seizures, or focal neurologic findings related to the size and location of the tumor and to associated peritumoral edema. These tumors usually do not have associated hemorrhage or calcification, but produce considerable edema and mass effect and enhance after the administration of intravenous contrast (≥65% of anaplastic gliomas and 96% of glioblastoma). Tumor cells have been found in the peritumoral edema, which corresponds to the T2-weighted MRI abnormalities. As a result, this volume is frequently used to define radiation treatment portals.

It is difficult to assess the results of therapy using CT or MRI scans, because the extent and distribution of contrast enhancement, edema, and mass effect are more a function of blood-brain barrier (BBB) integrity than of changes in the size of the tumor. Thus, other factors that exacerbate BBB dysfunction (eg, surgery, radiation, and tapering of corticosteroids) can mimic tumor progression through increasing contrast enhancement, T2-weighted abnormalities, and mass effect.

Anaplastic oligodendrogliomas are relatively rare; they are characterized by high cellularity, nuclear pleomorphism, frequent mitosis, endothelial proliferation, and necrosis. On histopathologic assessment, these tumors can be confused with glioblastoma multiforme; however, characteristic allelic losses of chromosomes 1p and 19q are present in anaplastic oligodendrogliomas. This distinct histologic subtype has a much better prognosis than anaplastic astrocytomas and glioblastomas because of its marked sensitivity to chemotherapy; half of the patients are alive at 5 years.

Treatment Overview

Surgery: The goals of surgery are to obtain a diagnosis, alleviate symptoms related to increased intracranial pressure or compression, increase survival, and decrease the need for corticosteroids. A prospective study in 565 patients with malignant glioma showed that aggressive surgery is a strong prognostic factor compared with biopsy alone (P<.0001). Retrospective analyses also suggest that gross total resection lengthens survival and is especially effective in patients with good PS. Unfortunately, the infiltrative nature of high-grade astrocytomas frequently renders gross total removal difficult. However, total resection is often possible for oligodendrogliomas, because most occur in the frontal lobes and the tumors are frequently well demarcated.

Unfortunately, nearly all glioblastomas recur. At recurrence, reoperation may improve the outcome for select patients. According to an analysis by Park et al, tumor involvement in specific critical brain areas, poor KPS, and large tumor volume were associated with unfavorable resection outcomes.

Radiation Therapy: Fractionated EBRT after surgery is standard adjuvant therapy for patients with high-grade astrocytomas. Use of RT is based on 2 randomized trials conducted in the 1970s that showed extension in survival. Walker et al compared postoperative supportive care, carmustine (BCNU), RT, and RT plus BCNU in 303 patients, and reported median survivals of 14.0, 18.5, 35.0, and 34.5 weeks, respectively. Another trial of 118 patients also found a benefit in median survival with RT after surgery compared with no RT (10.8 vs 5.2 months). The typical dose is 60 Gy in 1.8- to 2.0-Gy fractions. Use of hypofractionated courses of radiation (total 40–50 Gy) has been shown to be efficacious in older patients with glioblastoma. Studies including a ra-
diosurgery or brachytherapy boost to conventional RT did not show a survival benefit.\(^{62,63}\)

A lack of prospective data exist for reirradiating recurrent gliomas. Based on retrospective patient series, repeat RT using modern high-precision techniques such as fractionated stereotactic RT may be a palliative option for select patients with good PS and small recurrent tumors.\(^{64,65}\)

**Chemotherapy/Systemic Therapy:** Traditionally, chemotherapy was believed to be of marginal value in the treatment of newly diagnosed patients with high-grade gliomas, but this perception has shifted. In particular, combined chemoradiation has emerged as a new standard of care for patients with 1p/19q codeleted anaplastic oligodendroglioma or oligoastrocytoma and good PS nononelderly glioblastoma.

Most earlier trials studied nitrosourea-based chemotherapy regimens. The Medical Research Council reported results from the largest randomized trial of adjuvant chemotherapy in high-grade glioma.\(^{66}\) In this study, 674 patients were randomly assigned to either radiation alone or radiation plus PCV. No survival benefit was seen with the addition of PCV, even in patients with anaplastic astrocytomas. In contrast, 2 meta-analyses reviewed data from randomized trials of patients with high-grade glioma, and both found a modest survival benefit when chemotherapy was added to postoperative radiation.\(^{67,68}\) Specifically, the Glioma Meta-Analysis Trialists Group reviewed 12 studies involving approximately 3000 patients and reported an absolute increase in 1-year survival rate from 40% to 46% and a 2-month increase in median survival when chemotherapy was added to postoperative radiation (hazard ratio [HR], 0.85; 95% CI, 0.78–0.91; \(P<.0001\)).\(^{67}\) An earlier analysis by Fine et al\(^{68}\) on 16 randomized trials also found a 10% and 9% increase in survival at 1 and 2 years, respectively.

**Implanted Wafers:** Other routes of chemotherapy drug delivery have been evaluated. Local administration of BCNU using a biodegradable polymer (wafer) placed intraoperatively in the surgical cavity has shown a statistically significant improvement in survival for patients with recurrent high-grade gliomas (31 vs 23 weeks; adjusted HR, 0.67; \(P=.006\)).\(^{69}\) As a result, the FDA approved the BCNU wafer for this indication. A phase III placebo-controlled study in 32 patients with malignant glioma showed a statistically significant prolongation of survival when BCNU polymer was used as initial therapy in combination with RT.\(^{70}\)

A larger phase III trial in 240 newly diagnosed patients with malignant glioma also found a statistically significant improvement in median survival from 11.6 months in the placebo group to 13.9 months in the BCNU wafer–treated group.\(^{71}\) This benefit was maintained 2 and 3 years after implantation.\(^{72}\) Based on these studies, the FDA extended the approval of BCNU polymer wafers for use in malignant gliomas as initial therapy. However, clinicians and patients should be aware that BCNU can potentially interact with other agents, resulting in increased toxicity (see later discussion), and that implantation of the wafer may preclude future participation in clinical trials of adjuvant therapy.

**Temozolomide:** Temozolomide, an alkylating (methylyating) agent, is now the standard of care in conjunction with postoperative RT for younger patients with glioblastoma with good PS. Stupp et al\(^{73}\) conducted a phase III randomized study that assessed the drug in 573 patients with glioblastoma aged 70 years and younger with a WHO PS of 2 or less. Patients received either daily temozolomide administered concomitantly with postoperative RT followed by 6 cycles of adjuvant temozolomide, or RT alone. Side effects for temozolomide include hair loss, nausea, vomiting, headaches, fatigue, and anorexia. Because of the risk of lymphocytopenia and subsequent opportunistic infection, prophylaxis against *Pneumocystis carinii* pneumonia (PCP) is required when the agent is administered with RT. The chemoradiation arm resulted in a statistically better median survival (14.6 vs 12.1 months) and 2-year survival rate (26.5% vs 10.4%) than RT. Final analysis confirmed the survival advantage at 5 years (10% vs 2%).\(^{74}\) However, the study design does not shed light on which is responsible for the improvement: temozolomide administered with radiation, following radiation, or both. The temozolomide dose used in this trial is 75 mg/m\(^2\)/d concurrent with RT, then 150 to 200 mg/m\(^2\) post-RT on a 5-day schedule every 28 days. Alternate schedules such as a 21/28 dose-dense regimen or a 50-mg/m\(^2\) continuous daily schedule have been explored in a phase II trial for newly diagnosed glioblastoma.\(^{75}\) A comparison of the dose-dense 21/28 and standard 5/28 schedules has been completed with RTOG 0525 and the results showed no improvement with the post-RT dose-dense temozolomide arm when compared with the standard temozolomide arm.\(^{76}\)
Wick et al\textsuperscript{77} performed a phase III trial of sequential radiochemotherapy in 318 patients with anaplastic gliomas. The 3 randomized arms were: 1) RT; 2) PCV; and 3) temozolomide. At progression, patients in arm 1 received PCV or temozolomide, whereas patients in arms 2 and 3 were irradiated. The 3 strategies resulted in comparable time-to-progression and survival. Another phase III study conducted by the same group (NOA-08) randomized 412 patients with anaplastic astrocytoma (11%) or glioblastoma (89%) who were older than 65 years and had a good performance score (KPS $\geq$60) to receive temozolomide alone or radiation alone.\textsuperscript{78} Results showed that temozolomide treatment was noninferior to RT in terms of survival.

The international Nordic trial randomized 291 patients with glioblastoma and good PS across 3 groups: temozolomide, hypofractionated RT, or standard RT.\textsuperscript{84} Patients older than 70 years had better survival with temozolomide or fractionated RT compared with standard radiation.

MGMT (O-6-methylguanine-DNA methyltransferase) is a DNA repair enzyme that can cause resistance to DNA-alkylating drugs. Oligodendrogliomas frequently exhibit MGMT hypermethylation and low expression levels, which may explain the enhanced chemosensitivity.\textsuperscript{79} In the temozolomide arm of both the Nordic and German trials, patients with MGMT promoter methylation had longer survival than those without (9.7 vs 6.8 months; HR, 0.56; 95% CI, 0.34–0.93).\textsuperscript{81} This difference was not observed in the radiation groups.

No published data directly compare the benefit of temozolomide to nitrosourea for postoperative chemoradiation in patients with newly diagnosed anaplastic astrocytomas. This RTOG study (RTOG 9813) was prematurely discontinued because of lack of availability of BCNU.

Safety concerns exist regarding adjuvant use of temozolomide in patients with implanted BCNU wafers. However, temozolomide combined with RT after BCNU wafer placement seemed to be safe in multiple studies.\textsuperscript{80–82} For patients older than 70 years but with good performance, some evidence from small monocentric studies suggests the usefulness of temozolomide in addition to adjuvant radiation despite old age.\textsuperscript{83,84} For frail patients, temozolomide may be administered alone. A retrospective review of patients aged 70 years or older with mean KPS of 70 found no survival difference between those receiving radiation alone and those taking monthly temozolomide only.\textsuperscript{85} Given the susceptibility of elderly patients to radiation-induced neurotoxicity, especially when the PS is poor, chemotherapy alone seems to be a reasonable option.

**Combination Chemoradiation:** Improved survival observed in 2 randomized clinical trials established combined PCV chemotherapy and radiation as the new standard for treating patients with pure or mixed anaplastic oligodendroglioma harboring the 1p/19q codeletion. RTOG 9402 randomized 291 patients to PCV followed by immediate RT or RT alone.\textsuperscript{86} No difference was observed between the arms for the entire cohort. However, an unplanned analysis showed that patients with the codeletion lived longer than those without, and among patients with codeleted tumors, median survival was doubled when PCV was added to radiation (14.7 vs 7.3 years; HR, 0.59; 95% CI, 0.37–0.95; $P=0.03$). This difference was not observed for patients without 1p/19q codeletion.

Similarly, EORTC 26951 randomly assigned 368 patients with pure or mixed anaplastic oligodendroglioma to RT or RT followed by PCV.\textsuperscript{87} At a median follow-up of 140 months, overall survival was longer in the combination arm than in the radiation arm (42.3 vs 30.6 months; HR, 0.75; 95% CI, 0.60–0.95). Median survival was not reached in patients with codeleted tumors who received PCV/RT compared with 112 months for those in the RT group. No survival advantage was found with the addition of PCV among patients without the codeletion.

**Systemic Therapy for Recurrence:** Unfortunately, currently available chemotherapy does not provide cures. Patients with malignant gliomas eventually experience disease recurrence or progression. In addition to temozolomide\textsuperscript{85,88,89} and nitrosoureas,\textsuperscript{69,90} regimens that are commonly used as second-line or salvage chemotherapy include combination PCV,\textsuperscript{91} cyclophosphamide (category 2B recommendation),\textsuperscript{92,93} and platinum-based regimens (category 2B recommendation).\textsuperscript{38} Anaplastic gliomas may also be treated with irinotecan\textsuperscript{94} or etoposide.\textsuperscript{95}

Bevacizumab, an antiangiogenic agent, received accelerated approval in 2009 for recurrent glioblastoma based on 2 phase II studies. AVF 3708g randomized 167 patients to bevacizumab with or without irinotecan. MRI-defined objective response was achieved in 28% and 38% of patients, respectively.\textsuperscript{96}
Median survival was around 9 months, similar to that of a previous phase II trial. A published report of the other pivotal study (NCI 06-C-0064E) recorded a median survival of 31 weeks in 48 heavily pretreated patients. Bevacizumab alone or in combination with chemotherapy has also shown activity in anaplastic gliomas. Although efficacious, bevacizumab is associated with potentially serious adverse events, including hypertension, impaired wound healing, colonic perforation, and thromboembolism. **Alternating Electric Field Therapy:** In 2011, the FDA approved a portable medical device that generates low-intensity electric fields, termed tumor treating fields (TTF), for the treatment of recurrent glioblastoma. Approval was based on results of a clinical trial that randomized 237 patients to TTF or chemotherapy. Similar survival was observed in the arms, and TTF therapy was associated with lower toxicity and improved quality of life.

**NCCN Recommendations**

**Primary Treatment:** When a patient presents with a clinical and radiologic picture suggestive of high-grade glioma, neurosurgical input is needed regarding the feasibility of maximal safe tumor resection. Whenever possible, major tumor removal should be performed. One exception is when CNS lymphoma is suspected; a biopsy should be performed first and management should follow the corresponding pathway if the diagnosis is confirmed. If high-grade glioma is supported by intraoperative frozen section diagnosis, BCNU wafer placement is an option (category 2B). The extent of tumor debulking should be documented with a postoperative MRI scan within 72 hours after surgery, with and without contrast. If major tumor removal is deemed too risky, a stereotactic or open biopsy or subtotal resection should be performed to establish the diagnosis. Multidisciplinary consultation is encouraged once the pathology results are available.

**Adjuvant Therapy:** After surgical intervention, the choice of adjuvant therapy depends on the tumor pathology, status of the 1p/19q loci, and PS of the patient. For patients with 1p/19q codeleted anaplastic oligodendroglioma or oligoastrocytoma, fractionated EBRT plus PCV given before or after RT is a category 1 recommendation. Fractionated radiation plus concurrent temozolomide is an acceptable option, whereas PCV or temozolomide alone is designated category 2B. In the case of anaplastic astrocytoma, anaplastic oligodendroglioma, or oligoastrocytoma without 1p/19q codeletion, fractionated EBRT remains the standard (category 1). Other choices include fractionated radiation plus concurrent temozolomide, and PCV or temozolomide chemotherapy (deferred radiation). Patients with a poor KPS (<70) can be managed with radiation (hypofractionation is preferred over standard fractionation); PCV or temozolomide chemotherapy (category 2B); or palliative/best supportive care.

If glioblastoma is diagnosed, the adjuvant options mainly depend on the patient PS. Patients with good PS (KPS ≥70) are further stratified by age. Fractionated RT plus concurrent and adjuvant temozolomide is a category 1 recommendation for patients aged 70 years or younger. The panel noted that although data are focused on 6 cycles of post-RT temozolomide, 12 cycles are increasingly common, especially in recent clinical trial designs. Options for those older than 70 years include fractionated radiation plus concurrent and adjuvant temozolomide (category 2A for this group), hypofractionated RT (category 1), or chemotherapy with deferred RT. Patients opting for chemotherapy should receive temozolomide if they had MGMT methylation.

For patients with glioblastoma and with KPS lower than 70, options include fractionated EBRT, chemotherapy, or palliative/best supportive care. In the absence of data, panelists debated whether chemoradiation is appropriate for elderly patients with poor PS and ultimately agreed not to include this option.

The panel noted that given the complexity of symptoms and handicaps that can arise from malignant gliomas, PS score is a suboptimal measure of fitness for all patients. Similarly, a patient’s ability to tolerate toxic therapy does not necessarily correlate with chronologic age.

**Follow-Up and Recurrence:** Patients should be followed closely with serial MRI scans (at 2–6 weeks post-RT, then every 2–4 months for 2–3 years, then less frequently) after the completion of RT. Because RT can produce additional BBB dysfunction, corticosteroid requirements may actually increase; therefore, scans may appear worse during the first 3 months after completion of RT, even though no actual tumor progression is present. Early MRI scans allow for appropriate titration of corticosteroid doses, depending on the extent of mass effect and brain edema. Later scans are used to identify tumor recurrence. Early detection...
of recurrence is warranted, because local and systemic treatment options are available for patients with recurrent disease. However, MR spectroscopy, MR perfusion, or PET can be considered to rule out radiation-induced necrosis or "pseudoprogression."\textsuperscript{107,108}

Management of recurrent tumors depends on the extent of disease and patient condition. For local recurrence, repeat resection, with or without wafer placement in the surgical bed, can be performed if possible. After resection, or if the local recurrence is unresectable, patients with poor PS should undergo palliative/best supportive care without further active treatment. If PS is favorable, systemic chemotherapy may be administered (especially for anaplastic oligodendrogliomas); reirradiation is a category 2B option to consider if prior radiation produced a good/durable response. Patients with recurring glioblastoma may also consider alternating electric field therapy (category 2B). In the case of diffuse or multiple recurring lesions, the options are: 1) palliative/best supportive care for patients with poor PS; 2) systemic chemotherapy; 3) surgery to relieve mass effect; or 4) consider alternating electric field therapy for glioblastomas (category 2B).

All patients should receive best supportive care.

**Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors**

Cranial primitive neuroectodermal tumors (PNETs) are embryonal neoplasms showing varying degrees of differentiation. They are described by their location as infratentorial (medulloblastomas) and supratentorial (cerebral neuroblastoma, pineoblastoma, or esthesioneuroblastoma). The WHO classification system further divided these tumors into histologic variants.\textsuperscript{5} CNS PNETs are infrequent in children and very rare in adults, with an overall incidence of 0.26 per 100,000 person-years reported by the Central Brain Tumor Registry of the United States.\textsuperscript{109} Overall, it represents only 1.8% of all brain tumors, although it is the most common type among pediatric brain malignancies.

Approximately half of the affected patients will present with elevated intracranial pressure. Headache, ataxia, and nausea are commonly observed symptoms.\textsuperscript{110} All PNETs of the brain are WHO grade IV, because they are invasive and rapidly growing. They also have the tendency to disseminate through the cerebrospinal fluid (CSF). Larger retrospective case series of adult patients reported a 10-year survival rate of 48% to 55%, with frequent recurrence beyond 5 years, commonly in the posterior fossa.\textsuperscript{111,112}

**Treatment Overview**

**Surgery:** Evidence in adult patients is meager for this rare disease and no randomized trial data are available, but a general consensus exists that surgical resection should be the routine initial treatment to establish diagnosis, relieve symptoms, and maximize local control. Complete resection can be achieved in half of the patients\textsuperscript{10,113-116} and is associated with improved survival.\textsuperscript{113,115} In addition, surgical placement of a ventriculoperitoneal shunt can be used to treat hydrocephalus.

**Radiation Therapy:** Adjuvant radiation after surgery is the current standard of care, although most studies are based on the pediatric population. The conventional dose is 30 to 36 Gy of craniospinal irradiation and a boost to a total of 55.8 Gy to the primary brain site.\textsuperscript{113,115} A lower craniospinal dose of 23.4 Gy, combined with chemotherapy, has gained popularity for average-risk patients to lessen side effects while maintaining 55.8 Gy to the posterior fossa,\textsuperscript{111,116,117} although one randomized trial found an increased relapse risk with dose reduction.\textsuperscript{118} SRS demonstrated safety and efficacy in a small series of 12 adult patients with residual or recurrent disease.\textsuperscript{119}

**Systemic Therapy:** The use of postirradiation chemotherapy to allow radiation dose reduction is becoming increasingly common especially for children,\textsuperscript{116,117} but optimal use of adjuvant chemotherapy is still unclear for adult patients.\textsuperscript{110-112,120,121} A phase III study that enrolled more than 400 patients between ages 3 and 21 years to receive postirradiation cisplatin-based chemotherapy regimens recorded an encouraging 86% 5-year survival.\textsuperscript{122}

Several regimens are being used in the recurrence setting, most of which include etoposide.\textsuperscript{123-125} Temozolomide has also been used in this setting.\textsuperscript{126} High-dose chemotherapy in combination with autologous stem cell transplantation is a feasible strategy for patients who have had a good response with lower doses.\textsuperscript{125,127}

**NCCN Recommendations**

**Primary Treatment:** MRI scan is the gold standard for assessing and diagnosing PNET. The typical tumor shows enhancement and heterogeneity.
Fourth ventricular floor infiltration is a common finding related to worse prognosis. Multi-disciplinary consultation before treatment initiation is advised. Maximal safe resection is recommended wherever possible. Contrast-enhanced brain MRI should be performed within 24 to 72 hours after surgery, but spinal MRI should be delayed by 2 to 3 weeks. Because of the propensity of PNET to CSF seeding, CSF sampling after spine imaging via lumbar puncture is also necessary for staging. Medulloblastoma should be staged according to the modified Chang system using information from both imaging and surgery.

Adjuvant Therapy: Patients should be stratified according to recurrence risk for planning of adjuvant therapy (reviewed by Brandes et al). The NCCN CNS Panel agrees that patients with large cell or anaplastic medulloblastoma, supratentorial PNET, disease dissemination, unresectable tumors, or residual tumors larger than 1.5 cm² postsurgery are at heightened risk. These patients should undergo irradiation of the neuraxis followed by chemotherapy. Collection of stem cells before radiation should be considered for potential future autologous stem cell reinfusion at disease progression. For patients at average risk, craniospinal radiation alone or concurrent chemoradiation followed by chemotherapy are both viable options.

Recurrence and Progression: No robust data support an optimal follow-up schedule for PNETs. General guidelines include brain MRI every 3 months for the first 2 years, biannual brain MRI for the next 3 years, then yearly brain scans. If recurrent disease is detected on these scans, CSF sampling is also required. Concurrent spine imaging should be performed as clinically indicated for patients with previous spinal disease. Bone scans, CT scans, and bone marrow biopsies should be conducted as indicated.

Maximal safe resection should be attempted on recurrent brain tumors. High-dose chemotherapy with autologous stem cell rescue is also feasible for patients showing no evidence of disease after resection or conventional reinduction chemotherapy. On disease progression, options include chemotherapy alone, radiation alone (including SRS), and chemoradiation. Patients with metastases should be managed with chemotherapy or best supportive care, such as palliative radiation.

Brain Metastases
Metastases to the brain are the most common intracranial tumors in adults and may occur up to 10 times more frequently than primary brain tumors. Population-based data reported that 8% to 10% of cancer patients are affected by symptomatic metastatic tumors in the brain. A much higher incidence based on autopsy has been reported. As a result of advances in diagnosis and treatment, most patients improve with treatment and do not die of these metastatic lesions. Primary lung cancers are the most common source, although melanoma has been documented to have the highest predilection to spread to the brain. Diagnosis of CNS involvement is becoming more common in patients with breast cancer as therapy for metastatic disease is improving.

Nearly 80% of brain metastases occur in the cerebral hemispheres, an additional 15% occur in the cerebellum, and 5% occur in the brainstem. These lesions typically follow a pattern of hematogenous spread to the gray-white junction where the relatively narrow caliber of the blood vessels tends to trap tumor emboli. Most cases have multiple brain metastases evident on MRI scans. The presenting signs and symptoms of metastatic brain lesions are similar to those of other mass lesions in the brain, such as headache, seizures, and neurologic impairment.

Treatment Overview
Surgery: Advances in surgical technique have rendered upfront resection followed by WBRT the standard of care for solitary brain metastases. A retrospective analysis of 13,685 patients admitted for resection of metastatic brain lesions showed a decline in in-hospital mortality from 4.6% in the period of 1988 through 1990 to 2.3% in the period of 1997 through 2000. High-volume hospitals and surgeons produced superior outcomes.

Patchell et al conducted a study that randomized 95 patients with single intracranial metastases to complete resection alone or surgery plus adjuvant WBRT. Postoperative radiation was associated with dramatic reduction in tumor recurrence (18% vs 70%; \( P < .001 \)) and likelihood of neurologic deaths (14% vs 44%; \( P = .003 \)). No difference in overall survival, a secondary end point, was seen between the arms. Comparison of surgery plus WBRT versus WBRT alone is discussed in the WBRT section, opposite page.
In the case of multiple lesions, the role of surgery is more restricted to obtaining biopsy samples or relieving mass effect from large symptomatic metastases. However, evidence from retrospective series suggested survival benefits from tumor resection for selected patients with good prognosis with up to 3 metastatic sites.\textsuperscript{137,138} 

**Stereotactic Radiosurgery:** The advent of SRS offered a minimally invasive alternative to surgery. Patients undergoing SRS avoid the risk of surgery-related morbidity. Late side effects such as edema and radiation necrosis are uncommon.\textsuperscript{139} 

Accumulating retrospective evidence suggests that low disease volume instead of number of metastatic lesions is predictive of survival benefits.\textsuperscript{140,141} Hence, patients with multiple lesions but a low total disease volume may be amenable to SRS. Other predictors of longer survival with SRS include younger age, good PS, and primary tumor control.\textsuperscript{141–144} 

In a randomized Japanese study of 132 patients with 1 to 4 metastatic brain tumors smaller than 3 cm, addition of WBRT to SRS did not prolong median survival compared with SRS alone (7.5 vs 8.0 months, respectively).\textsuperscript{145} However, the 1-year brain recurrence rate was lowered in the WBRT plus SRS arm (47% vs 76%; \(P<.001\)). Another small randomized trial of 58 patients with 1 to 3 brain metastases was stopped early because of a significant decline in learning and memory function among the group receiving both SRS and WBRT compared with the SRS group (52% vs 24%).\textsuperscript{146} Analysis showed that SRS plus WBRT was associated with a better 1-year recurrence-free survival rate (73%) than SRS alone (27%). A third trial recruited 359 patients with 1 to 3 metastatic brain lesions who underwent surgery or SRS.\textsuperscript{147} They were randomized to either adjuvant WBRT or observation. Compared with the observation arm, intracranial relapse rates and neurologic mortality were lower in the WBRT arm, but overall survival and duration of functional independence were similar. A meta-analysis concluded no overall survival improvement with the addition of WBRT to SRS.\textsuperscript{148} 

Retrospective comparative studies showed that SRS plus WBRT resulted in equivalent if not better survival compared with surgery and WBRT.\textsuperscript{149–151} SRS also conferred a significant improvement in local control, especially for patients with radiosensitive tumors or solitary brain lesions. SRS alone compared with resection plus WBRT was evaluated in a randomized controlled trial by Muacevic et al.\textsuperscript{152} The study was stopped prematurely because of poor accrual. In the final analysis based on 64 patients with solitary brain metastases, radiosurgery alone was less invasive and resulted in equivalent survival and local control, but it was associated with a higher rate of distant relapse. 

Small patient series have shown local control rates greater than 70% with SRS in the recurrence setting for patients with good PS and stable disease who have received prior WBRT.\textsuperscript{153–157} 

**Whole-Brain Radiation Therapy:** Historically, WBRT was the mainstay of treatment for metastatic lesions in the brain. It continues to play multiple roles in the modern era, such as primary intervention when surgery or SRS is not feasible (eg, polymetastatic brain metastases), as adjunctive therapy to prevent recurrence, and as treatment for recurrent disease. 

Three randomized trials investigated the effectiveness of WBRT with or without surgery in patients with single brain metastases. In a study of 48 patients, Patchell et al.\textsuperscript{159} showed that surgery followed by WBRT lengthened overall survival (40 vs 15 weeks in WBRT arm; \(P<.01\)) and functional dependence (38 vs 8 weeks; \(P<.005\)), and decreased recurrence (20% vs 52%; \(P<.02\)) compared with radiation alone. Similarly, combined treatment led to longer survival and functional independence in another randomized study by Vecht et al.\textsuperscript{159} (n=63). The greatest difference was observed in patients with stable disease: median survival was 12 versus 7 months, and functional independence was 9 versus 4 months. A third study of 84 patients found no difference in survival between the strategies; however, patients with extensive systemic disease and lower performance level were included, which likely resulted in poorer outcomes in the surgical arm.\textsuperscript{160} 

The impact of SRS boost in addition to WBRT was evaluated in 2 published randomized controlled studies. A multi-institutional trial by RTOG (RTOG 9508) randomly assigned 333 patients with 1 to 3 brain metastases to WBRT plus SRS or WBRT only.\textsuperscript{161} Despite the inclusion of larger tumors (3–4 cm) that are not favorable to SRS, the authors found a significant survival benefit in the combined arm (6.5 vs 4.9 months; \(P=.04\)) when treating a single metastasis; this benefit was not observed in patients...
with multiple (2 or 3) lesions. A much smaller trial of 27 patients with 2 to 4 lesions found no significant difference in survival, although SRS did extend time to local failure (36 vs 6 months; \( P=0.005 \)).\(^{162} \)

Taken together, WBRT in conjunction with surgery or SRS leads to better clinical outcomes than WBRT alone for good performance patients with solitary metastatic intracranial lesions. However, many patients are not candidates for resection because of the inaccessibility of the tumor, extensive systemic disease, or other factors. WBRT is the main choice of primary therapy for this patient group.

No randomized data are available in the recurrent setting, but case series reported 31% to 70% of symptom-relieving response to irradiation.\(^{163–165} \)

**Systemic Therapy:** Systemic therapy is rarely used as primary therapy for brain metastases. In randomized studies, the addition of carboplatin or temozolomide to WBRT did not improve overall survival compared with radiation alone,\(^{166,167} \) although an increase in progression-free survival or radiologic response has been reported with temozolomide.\(^{167,168} \) Many tumors that metastasize to the brain are not very chemosensitive or have been already heavily pretreated with organ-specific effective agents. Poor penetration through the BBB is an additional concern. Therefore, chemotherapy is usually considered as a last line of therapy for recurrent disease when other options have been exhausted (ie, surgery, SRS, radiation). The choice of agent depends on the histology of the primary tumor. BCNU wafer implantation is a reasonable option at recurrence when resection is considered.\(^{169} \)

Among various agents, temozolomide may be useful in some patients with previously untreated brain metastases from metastatic melanoma.\(^{170} \) Temozolomide given on a prolonged schedule in combination with thalidomide has been tested in a phase II study of patients with brain metastases, but the high toxicity and lack of response rendered the regimen inappropriate.\(^{171} \)

A study of high-dose methotrexate in patients mostly with breast cancer achieved disease control in 56% of patients.\(^{172} \) Other agents shown to have activity in breast cancer include platinum plus etoposide\(^{173,174} \) and capecitabine with or without lapatinib.\(^{175–177} \)

A phase I/II study of topotecan plus WBRT has shown a 72% response rate in 75 patients with brain metastases.\(^{178} \) Unfortunately, a follow-up phase III trial was closed early because of slow accrual.\(^{179} \)

**NCCN Recommendations**

**Workup:** Patients who present with a single mass or multiple lesions on MRI or CT imaging suggestive of metastatic cancer to the brain, and who do not have a known primary, require a careful systemic workup with chest radiograph or CT, abdominal or pelvic CT, or other tests as indicated. FDG-PET can be considered if more than one brain lesion is present and no primary has yet been found. If no other readily accessible tumor is available for biopsy, a stereotactic or open biopsy resection is indicated to establish a diagnosis. Among patients with a known history of cancer and if concerns exist regarding the diagnosis of CNS lesions, a stereotactic or open biopsy resection or subtotal resection is also needed. Because brain metastases are often managed with multiple modalities, the NCCN CNS Panel encourages multidisciplinary consultation before treatment for optimal planning.

**Treatment for Limited (1–3) Metastatic Lesions:**

For patients with limited systemic disease or for whom reasonable systemic treatment options exist, aggressive management should be strongly considered. For surgical candidates, high-level evidence supports category 1 recommendations for surgical resection plus postoperative WBRT and for SRS plus WBRT if only one brain lesion is involved. SRS alone or after resection are also reasonable options. Macroscopic total removal is the objective of surgery. The choice between open resection and SRS depends on multiple factors, such as tumor size and location. The best outcome for SRS is achieved for small, deep lesions at institutions with experienced staff. If the tumor is unresectable, WBRT and/or radiosurgery can be used.

Patients with progressive extracranial disease whose survival is less than 3 months should be treated with WBRT alone, but surgery may be considered for symptom relief. The panel did not reach a consensus on the value of chemotherapy (category 2B). It may be considered in select patients using regimens specific to the primary cancer. In patients with systemic cancers and druggable targets (eg, epidermal growth factor receptor mutations in non–small cell lung cancer and BRAF mutations in metastatic melanoma), targeted therapy in neurologically asymptomatic patients with brain metastases is considered reasonable before administration of RT.
Patients should be followed with MRI every 3 months for 1 year and then as clinically indicated. Recurrence seen on radiograph can be confounded by the treatment effects of SRS. Consider tumor tissue sampling if there is a high index of suspicion of recurrence. On detection of recurrent disease, prior therapy clearly influences the choice of further therapies. Patients with recurrent CNS disease should be assessed for local versus systemic disease, because therapy will differ. For local recurrences, patients who were previously treated with surgery can receive the following options: 1) surgery; 2) single-dose or fractionated SRS; 3) WBRT; or 4) chemotherapy. However, patients who previously received WBRT probably should not undergo WBRT at recurrence because of concern regarding neurotoxicity. If the patient had previous SRS with a durable response for more than 6 months, reconsider SRS if imaging supports active tumor and not necrosis. Repeat SRS to a prior location is a category 2B recommendation. The algorithm for distant brain recurrences branches depending on whether patients have either 1 to 3 lesions or more than 3 lesions. In both cases, patients may receive WBRT or consider local/systemic chemotherapy, but patients with 1 to 3 recurrent tumors have the additional options of surgery or SRS.

WBRT should be used (30–45 Gy, given in 1.8- to 3.0-Gy fractions) depending on the patient’s PS, if this modality was not used for initial therapy. Local or systemic chemotherapy may be considered for select patients if the multiple lesions cannot be controlled by a combination of surgery and radiosurgery.180

If systemic CNS disease progression occurs in the setting of limited systemic treatment options and poor PS, WBRT should be administered for patients who have not been previously irradiated. For patients who have received prior WBRT, reirradiation is an option only if they had a positive response to the first course of RT treatment. Palliative/best supportive care is also an option in either case.

**Treatment for Multiple (>3) Metastatic Lesions:**

All patients diagnosed with more than 3 metastatic lesions should be treated with WBRT or SRS as primary therapy. The standard regimens for WBRT are 30.0 Gy in 10 fractions or 37.5 Gy in 15 fractions. For patients with poor neurologic performance, a more rapid course of RT can be considered (20.0 Gy, delivered in 5 fractions). SRS may be considered in patients with good PS and low overall tumor volume. Palliative neurosurgery should be considered if a lesion is causing a life-threatening mass effect, hemorrhage, or hydrocephalus.

After WBRT or SRS, patients should have a repeat contrast-enhanced MRI scan every 3 months for 1 year. If a recurrence is found, the algorithm branches depending on whether patients have 1) systemic disease progression with limited systemic treatment options, or 2) stable systemic disease or reasonable systemic treatment options. For patients with systemic disease progression, options include palliative/best supportive care or reirradiation. For patients with stable systemic disease, options include surgery, reirradiation, or chemotherapy.

**References**

Central Nervous System Cancers


77. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with...


148. Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients
<table>
<thead>
<tr>
<th>Panel Member</th>
<th>Clinical Research Support</th>
<th>Advisory Boards, Speakers Bureau, Expert Witness, or Consultant</th>
<th>Patent, Equity, or Royalty</th>
<th>Other</th>
<th>Date Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mario Ammirati, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/29/12</td>
</tr>
<tr>
<td>Philip J. Bieman, MD</td>
<td>Otsuka Pharmaceuticals; and Seattle Genetics</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5/1/13</td>
</tr>
<tr>
<td>Henry Brem, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/27/12</td>
</tr>
<tr>
<td>Nicholas Butowski, MD</td>
<td>None</td>
<td>Roche Laboratories, Inc.</td>
<td>None</td>
<td>None</td>
<td>8/17/13</td>
</tr>
<tr>
<td>Marc C. Chamberlain, MD</td>
<td>NCCN-funded Bendamustine trial for recurrent high-grade gliomas</td>
<td>Pharmacokinetics Advisory Board</td>
<td>None</td>
<td>None</td>
<td>8/9/12</td>
</tr>
<tr>
<td>Lisa M. DeAngelis, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/20/12</td>
</tr>
<tr>
<td>Robert A. Fenstermaker, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/28/13</td>
</tr>
<tr>
<td>Allan Friedman, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/26/12</td>
</tr>
<tr>
<td>Mark R. Gilbert, MD</td>
<td>RTOG Trial</td>
<td>Abbott Laboratories; Genentech, Inc.; Merck &amp; Co., Inc.; and EMD Serono</td>
<td>None</td>
<td>None</td>
<td>8/18/13</td>
</tr>
<tr>
<td>Deneen Hesser, MSHSA, RN, OCN</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/27/12</td>
</tr>
<tr>
<td>Matthias Holdhoff, MD, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>11/7/12</td>
</tr>
<tr>
<td>Larry Junck, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/14/13</td>
</tr>
<tr>
<td>Ronald Lawson, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/29/13</td>
</tr>
<tr>
<td>Jay S. Loeffler, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/20/13</td>
</tr>
<tr>
<td>Moshe H. Mao, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/24/13</td>
</tr>
<tr>
<td>Paul L. Moots, MD</td>
<td>ECOG; and EMD Serono</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/9/12</td>
</tr>
<tr>
<td>Tara Morrison, MD</td>
<td>None</td>
<td>Merck &amp; Co., Inc.</td>
<td>None</td>
<td>None</td>
<td>10/1/12</td>
</tr>
<tr>
<td>Maciej M. Mrugala, MD, PhD, MPH</td>
<td>None</td>
<td>Enzon Pharmaceuticals; and Schering-Plough Corporation</td>
<td>None</td>
<td>None</td>
<td>11/24/09</td>
</tr>
<tr>
<td>Louis Burt Nabors, MD</td>
<td>AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim GmbH; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; ImClone Systems Incorporated; Merck KGaA; and Transmolecular</td>
<td>Merck KGaA</td>
<td>None</td>
<td>None</td>
<td>3/3/13</td>
</tr>
<tr>
<td>Herbert B. Newton, MD</td>
<td>None</td>
<td>Eisai Inc.; Genentech, Inc.; and Merck &amp; Co., Inc.</td>
<td>None</td>
<td>None</td>
<td>8/16/12</td>
</tr>
<tr>
<td>Jana Portnow, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>11/28/12</td>
</tr>
<tr>
<td>Jeffrey J. Raizer, MD</td>
<td>Eli Lilly and Company; Genentech, Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Arno; Cellex; Diffusion; Geron; and Myriad</td>
<td>Enzon Pharmaceuticals; Genentech, Inc.; Merck &amp; Co., Inc.; and Novartis Pharmaceuticals Corporation</td>
<td>None</td>
<td>None</td>
<td>10/3/12</td>
</tr>
<tr>
<td>Lawrence Recht, MD</td>
<td>Genentech, Inc.; and Celtic Pharmaceuticals</td>
<td>Genentech, Inc.</td>
<td>None</td>
<td>None</td>
<td>2/27/13</td>
</tr>
<tr>
<td>Dennis C. Shrieve, MD, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2/26/13</td>
</tr>
<tr>
<td>Allen K. Sils Jr, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/19/13</td>
</tr>
<tr>
<td>David Tran, MD, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/26/12</td>
</tr>
<tr>
<td>Nam Tran, MD, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/8/12</td>
</tr>
<tr>
<td>Frank D. Vrionis, MD, MPH, PhD</td>
<td>Globus; and Synthes</td>
<td>Florida Board of Medicine; and Southeastern Brain Tumor Association</td>
<td>None</td>
<td>Orthofix</td>
<td>11/13/12</td>
</tr>
<tr>
<td>Patrick Y. Wen, MD</td>
<td>None</td>
<td>Amgen Inc; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim GmbH; Eisai Inc.; Bexilixi Inc.; Genentech, Inc.; MedImmune Inc.; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; EMD Serono; Geron; Vascular Biogenics; and sanofi-aventis U.S.</td>
<td>None</td>
<td>None</td>
<td>6/3/13</td>
</tr>
</tbody>
</table>

The NCCN Guidelines Staff have no conflicts to disclose.